In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan

Jien Wei Liu, Lih Shinn Wang, Yu Jen Cheng, Gwo Jong Hsu, Po Liang Lu, Yung Ching Liu, Chih Ming Chen, Chun Ming Lee, Wu Sun, Tsrang Neng Jang, Ping Cherng Chiang, Yin Ching Chuang, Hsiu Chen Lin, Zhi Yuan Shi, Hsiang Chi Kung, Cheng Hua Huang, Shih Ming Tsao, Chin Te Lu, Chun Hsing Liao, Po Ren Hsueh

研究成果: 雜誌貢獻文章同行評審

16 引文 斯高帕斯(Scopus)


We performed susceptibility testing using the microdilution method to determine the in-vitro activity of tigecycline against 393 Acinetobacter baumannii clinical isolates collected in 2006 from 19 hospitals in Taiwan. Significant proportions of the isolates were resistant to imipenem (44%), ciprofloxacin (75%), amikacin (69%), sulbactam (34%) and all four antibiotics (22%), and susceptibility to tigecycline among these different resistant phenotypes of A. baumannii varied from 71% to 82%. The minimum inhibitory concentration (MIC) of tigecycline ranged from 0.6 to 16 μg/mL (MIC50 2 μg/mL; MIC90 4 μg/mL). The cumulative curve of tigecycline MICs showed that when the MIC cut-offs were set at 2 μg/mL and 4 μg/mL, 80.9% and 93.1% of the isolates were susceptible, respectively. As tigecycline will be used in the future for infections caused by multidrug-resistant A. baumannii because of limited antibiotic choice, and as resistance to tigecycline in A. baumannii isolates may develop following antibiotic exposure, continuous monitoring of the susceptibility of A. baumannii isolates to tigecycline is warranted.
頁(從 - 到)S188-S191
期刊International Journal of Antimicrobial Agents
發行號SUPPL. 3
出版狀態已發佈 - 11月 2008

ASJC Scopus subject areas

  • 微生物學(醫學)
  • 傳染性疾病
  • 藥學(醫學)


深入研究「In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan」主題。共同形成了獨特的指紋。